Evidence map›Paper›PMID 9717974›Full record

ArticleClinical and experimental immunology1998

A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B.

H M Diepolder, M C Jung, E Keller, W Schraut, J T Gerlach, N Grüner, R Zachoval, R M Hoffmann, C A Schirren, S Scholz and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Immunological cure of HBV infection.Hepatology international · 2019
    Review
  5. CD4Frontiers in immunology · 2019
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

H M DiepolderDepartment of Medicine II, Klinikum Grosshadern, University of Munich, Germany.
M C Jung
E Keller
W Schraut
J T Gerlach
N Grüner
R Zachoval
R M Hoffmann
C A Schirren
S Scholz
G R Pape
Institute of Immunology · HRKlinikum Vest · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A strong virus-specific CD4+ and CD8+ T lymphocyte response to hepatitis B virus (HBV) has been associated with viral clearance, but little is known about factors determining the individual's ability to mount such a T cell response. Recently a strong association between the HLA class II allele DR13 and a self-limited course of HBV infection has been described. In the present study of 33 patients with acute hepatitis B we show that individuals carrying HLA-DR13 mount a more vigorous CD4+ T cell response to HBV core (5706 ct/min (25th/75th percentile 3239 ct/min; 10,552 ct/min)) than patients without HLA-DR 13 (1365 ct/min (490 ct/min; 5334 ct/min); P = 0.006). However, peptide epitopes aa 50-69, aa 61-85, and aa 81-105 were recognized most frequently by both patient groups. Moreover, among 14 HBV core-specific CD4+ T cell clones from two patients with HLA-DR13, only one T cell clone was HLA-DR13-restricted. Our data suggest that the beneficial effect of the HLA-DR13 alleles on the outcome of HBV infection could be explained by a more vigorous HBV core-specific CD4+ T cell response, which may either be due to more proficient antigen presentation by the HLA-DR13 molecules themselves or a linked polymorphism in a neighbouring immunoregulatory gene.

Indexed as

Acute DiseaseAllelesCD4-Positive T-LymphocytesClone CellsEpitopesHepatitis BHepatitis B Core AntigensHistocompatibility TestingHLA-DR AntigensHLA-DR Serological SubtypesHumansJaundiceLeukocytes, MononuclearLymphocyte ActivationEpitopesHepatitis B Core AntigensHLA-DR13 antigenHLA-DR AntigensHLA-DR Serological Subtypes

Identifiers

PMID9717974
PMCPMC1905031
OpenAlexW2047865205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.